23 results about "Blood coagulation time" patented technology

The invention relates to a method for determining a fibrinogen concentration in a blood sample, comprising whole blood, the sample having been mixed with a reagent configured to cause fibrin formation, the method comprising: - a) forming images (I(t)) of the sample at various times (t); - b) establishing a correlation indicator (C(t)) between images acquired at various respective times (I(t), (I(t + dt))); - c) determining a variation as a function of time in the correlation indicator; - d) detecting a coagulation time (tcoag) on the basis of the variation as a function of time; - e) depending on the coagulation time, determining the fibrinogen concentration in the blood; the method being characterised in that: the reagent comprises batroxobin, the batroxobin concentration, after mixing, being between 25 and 1000 enzyme units per mL.

A blood coagulation time shortening agent for a blood specimen deficient in coagulation factor XII, in activated partial thromboplastin time measurement includes, as an active ingredient, a polymer having 2-methacryloyloxyethyl phosphorylcholine as a constitutional unit.

The invention relates to the technical field of biomass resource utilization and medical biological materials, in particular to a method for preparing a hemostatic sponge based on sunflower stem pith and application of the hemostatic sponge. The hemostatic sponge is prepared from sunflower stem pith fragments and an adhesive through a deconstruction-recombination technology and meets the requirements of isotropic liquid absorption, non-isotropic liquid absorption and non-isotropic liquid absorption; the difference between the axial blood suction rate and the radial blood suction rate is smaller than or equal to 10%, the shape memory recovery rate within 30 seconds after blood suction is larger than or equal to 85%, and the blood coagulation time is 60-100 seconds. According to the sunflower stem pith-based hemostatic sponge, sunflower byproducts serve as raw materials, the water absorption capacity and the hemostatic efficiency of the sponge are improved by means of the hydrophilicity and the procoagulant characteristic of the sunflower byproducts, and the raw material cost is reduced by 90% or above compared with that of existing synthetic sponge; the sunflower stem pith-based hemostatic sponge is constructed based on deconstruction and structural recombination, the limitation of a natural sunflower stem pith anisotropic microstructure is improved, the sponge has isotropic liquid absorption, the difference between axial and radial blood absorption rates is smaller than or equal to 10%, the sponge has shape memory ability, the sponge is compressed to 50% of the original volume after blood absorption, and the recovery rate is larger than or equal to 85% within 30 s.

The invention belongs to the field of biological medicine, and particularly relates to a chitosan-based hemostatic composition and a preparation method and application thereof.The chitosan-based hemostatic composition is prepared from 30-60 parts by mass of chitosan with the deacetylation degree of 80%-95% and the molecular weight of 10-100 kDa and 30-60 parts by mass of derivatives thereof, thrombin, fibrinogen and other blood coagulation promoting factors, and the chitosan-based hemostatic composition and the derivatives thereof are prepared into the hemostatic composition. The haemostatic composition is prepared by combining novel bioactive peptides (peptide sequences K and L) extracted from centella asiatica and scutellaria baicalensis, and auxiliary materials of sodium alginate and sodium hyaluronate according to a specific proportion through a specific process. Experiments show that the composition can remarkably shorten the blood coagulation time, is good in cell compatibility and has a good hemostatic effect in various bleeding models. The hydrogel has the advantages of high efficiency, good biocompatibility, multiple functions, high cost effectiveness and the like, and has wide application prospects in the fields of surgery, trauma and the like.

The invention provides application of phosvitin and phosphopeptides thereof in preparation of in-vitro anticoagulant drugs, specifically, blood coagulation is caused by a series of enzymatic reactions, the chemical nature of the blood coagulation is that fibrinogen in a sol state is converted into fibrin in a gel state, and the main substance for catalyzing the reactions is thrombin. The phosvitin can inhibit the activity of thrombin in blood so as to prolong the blood coagulation time to achieve the anticoagulation effect. The application proves that phosvitin has the potential of being developed into an in-vitro anticoagulant.

A method for determining the concentration of fibrinogen in a blood sample, comprising whole blood, the sample having been mixed with a reagent configured to induce fibrin formation, the method comprising: a) forming images of the sample at different times; b) establishing a correlation indicator between images respectively acquired at different times; c) determining a time evolution of the correlation indicator; d) detecting a coagulation time from the time evolution; e) as a function of the coagulation time, determining the concentration of fibrinogen in the blood; the method being characterized in that: the reagent comprises batroxobin, the concentration of batroxobin, after mixing, being between 25 and 1000 enzyme units per mL.

A blood collection tube (1) into which a blood sample has been placed is irradiated with near-infrared light having a specific wavelength of 1050-1350 nm by means of a near-infrared light source (4), and the process of a blood coagulation reaction can be observed by measuring the temporal change in light intensity passing through the inside of the blood sample detected by an infrared camera (6). Thus, in addition to measuring the blood coagulation time, it is possible to determine the completion or non-completion of the blood coagulation reaction on the basis of the tendency to increase or decrease the light intensity, and it is possible to automate the pre-treatment step of the centrifugal separation treatment.

The invention discloses an acute gastrorrhagia hemostatic agent based on a gardenia carbon nano composite material and a preparation method of the acute gastrorrhagia hemostatic agent, and belongs to the technical field of biological medicines. According to the preparation method disclosed by the invention, the gardenia carbon nano composite material is prepared through nanocrystallization transformation, and the average particle size is 2.35 nm + / -0.56 nm. Mouse tail cutting hemostasis and capillary experiments prove that the gardenia charcoal nano composite material has the effects of promoting hemostasis and blood coagulation, and the hemostasis time and the blood coagulation time can be remarkably shortened; through construction of a rat blood-heat gastrorrhagia model, it is verified that the gardenia charcoal nano composite material has a remarkable hemostatic effect; and zebra fish verifies that the gardenia carbon nano composite material can protect gastrointestinal mucosa from being damaged, specifically, the area of a small intestinal cavity is reduced, and the number of neutrophils in the intestinal tract is reduced. The gardenia carbon nano composite material provided by the invention can be used for preparing a medicine for promoting blood coagulation and / or hemostasis, a hemostatic for acute gastrorrhagia and a medicine for relieving gastrointestinal mucosal injury.

The invention belongs to the technical field of application of traditional Chinese medicines, and particularly relates to application of a Dan'e Fukang preparation in preparation of a medicine for treating dysfunctional uterine bleeding. Pharmacological experiments prove that Dan'e'fukang can shorten the blood coagulation time and bleeding time of mice, and increase the uterine coefficient, estradiol level and progesterone level of rats without ovulation type dysfunctional uterine bleeding and the VEGF protein expression quantity of endometrial tissues of the rats. The Dan'e Fukang provides more medication choices for clinical treatment of dysfunctional uterine bleeding diseases, and has the advantages of good effect, many years of clinical use experience and high safety.

The invention relates to the technical field of heparin and protamine analysis, in particular to a method for determining the dosage of heparin and protamine. The method comprises the steps that a first sample set A is obtained, Ai is the ith first sample, and Ai is obtained by adding different doses of preset chemical substances into a blood sample of a target individual; acquiring a whole blood activation blood coagulation time detection result set B; obtaining a target model according to the whole blood activation coagulation time detection result in the step B, the dosage of the corresponding added preset chemical substance and the preset model; and according to the target whole blood activated coagulation time and the target model, obtaining the dosage of a preset chemical substance corresponding to the target whole blood activated coagulation time of the target individual. According to the method, the heparin dosage and the protamine dosage which are suitable for the target individual and correspond to the target whole blood activation coagulation time can be determined, and reference is provided for the heparin dosage and the protamine dosage in an actual application scene.

A method for controlling MNPT is required.Coexistence of a specific metal ion with tissue thromboplastin enables MNPT to be controlled / adjusted to a desired time. Coexistence of the specific metal ion with tissue thromboplastin also enables improvement of stability when a thromboplastin reagent is stored in a solution form.

Provided are: a reagent composition for measuring activated partial thromboplastin time, the reagent composition containing an antibody that binds to a blood coagulation factor as an antigen or an antigen-binding fragment thereof; and an inspection method including a step for mixing the reagent composition and a plasma specimen to be inspected at a prescribed ratio and measuring if the blood coagulation time thereof is T, and a step for determining that the plasma specimen is abnormal when the blood coagulation time T is longer than a designated reference.

The application discloses a blood coagulation detector, which comprises a driving motor, a blood coagulation cylinder, a connecting rod, a sealing cover, a magnet, a base plate, a pressing plate, a polymer film, an elastic metal plate, an electrode, a working plane and an electrometer, wherein the driving motor is fixedly installed on the working plane, the rotating shaft of the driving motor is provided with the blood coagulation cylinder, the blood coagulation cylinder is provided with the magnet, the working plane is further provided with the base plate and the pressing plate which are fixedly bonded at an included angle, the included angle between the base plate and the pressing plate is an acute angle, the base plate is pasted with the polymer film, the pressing plate is inserted with the elastic metal plate, the elastic metal plate has elasticity, the front end of the elastic metal plate extends towards the polymer film, the front end of the elastic metal plate is fixedly provided with the electrode, the electrode is in contact with the polymer film, and the electrode is connected with the electrometer through the wire. The electrode and the polymer film are periodically contacted and separated to generate an electric signal, and the electric signal is read through the electrometer, so that the blood coagulation time and other parameters can be detected, and the sensitivity is high.

Provided is a method for accurately measuring coagulation time of blood samples showing various coagulation reactions. The method for measuring blood coagulation time includes measuring coagulation reaction of a sample prepared by mixing a subject specimen and a coagulation time measurement reagent; calculating weighted average time of a calculation target area of a waveform related to coagulation velocity from the resulting measurement data; and determining the weighted average time as blood coagulation time.

An activated partial thromboplastin time measurement reagent contains a polymer having 2-methacryloyloxyethyl phosphorylcholine as a constitutional unit. A blood coagulation time regulator for a lupus anticoagulant-positive blood specimen or a heparin-containing blood specimen in activated partial thromboplastin time measurement includes, as an active ingredient, a polymer having 2-methacryloyloxyethyl phosphorylcholine as a constitutional unit.

The invention provides novel multi-layer composite hemostatic gauze based on modified zeolite and a preparation method thereof. The gauze comprises a modified zeolite core layer from inside to outside, the content of Ca < 2 + > is increased to 6-13 wt% through ion exchange, 0.4-1.2 wt% of prothrombin activator is loaded, platelet activation is promoted through high-calcium zeolite, and the blood coagulation time is shortened to 46.7% of that of a conventional product. A temperature control buffer layer, a calcium alginate / polyethylene glycol hydrogel layer with the thickness of 5-10 [mu] m and a phase change material (octadecane microcapsule) containing 3-5 wt%, the phase change material generates phase change heat absorption at 42 DEG C, and the heat release peak value of zeolite is controlled to be 42 DEG C or below. The outer carrier is viscose fiber / silk blended gauze subjected to plasma treatment. The multi-layer composite zeolite hemostatic gauze can be applied to medical instruments for emergency treatment of war wounds, hemostasis in surgical operations and bleeding control of patients in anticoagulation treatment.

The invention discloses a medical rapid hemostasis device, and belongs to the technical field of hemostats. The medical rapid hemostasis device comprises a composite suture, and the composite suture is used for conducting a blood coagulation effect on blood vessels; the sealing plug can complete radial expansion plugging in a self-adaptive manner; and the anchoring device is used for connecting the composite suture and the sealing plug, so that the sealing plug sleeves the composite suture and pops up to a blood vessel groove to complete blood vessel sealing. The thrombin targeted release shortens the blood coagulation time; the sealing plug expands in a self-adaptive mode to cover a 1-5 mm blood vessel crevasse, and the sealing qualification rate is high. Operation is simplified, operation steps are reduced from seven steps to three steps through integrated design, and the first-aid efficiency is improved. The sodium alginate-PCL suture is completely degraded in vivo within 28 days, so that a secondary taking-out operation is avoided; the ePTFE-fibrinogen compound promotes endothelial crawling, and the revascularization rate after 6 weeks is larger than 90%. And the economic benefit is remarkable: the blood transfusion demand is reduced by timely and effective hemostasis.

The invention relates to application of a cytoskeleton regulator in preparation of a blood coagulation promoting drug, and belongs to the technical field of biological medicines, and the blood coagulation promoting drug is a drug for treating or preventing hemorrhagic diseases related to low blood coagulation function. The hemorrhagic diseases comprise traumatic hemorrhage, surgical operation related hemorrhage, hepatopathy related hemorrhage, postpartum hemorrhage, hemophilia, hemorrhage caused by excessive anticoagulant drugs, thrombocytopenia or dysfunction related hemorrhage; the cytoskeleton regulator is one or more of a compound for inhibiting polymerization of actin microfilaments, a compound for inhibiting shrinkage of myosin and a ROCK kinase inhibitor; the cytoskeleton regulator can be used for preparing a procoagulant treatment drug, the effect is played by inducing endogenous cells of a body to release procoagulant particles, a brand new strategy is provided for a clinical hemostatic drug, and the cytoskeleton regulator can remarkably shorten the coagulation time of whole blood; the bleeding time can be remarkably shortened, the total blood loss amount is reduced, and the powerful in-vivo bleeding stopping effect is achieved.

To estimate a cause of extension of coagulation time of the blood of a specimen to be inspected.SOLUTION: A method for estimating a cause of extension of blood coagulation time includes: acquiring a coagulation waveform indicating a change with time of a light amount due to a coagulation reaction of reaction liquid obtained by mixing a specimen to be inspected and an agent (S301b); acquiring a first waveform through before-and-after difference processing on the coagulation waveform (S302b); acquiring first and second fitting waveforms through fitting processing on the coagulation waveform and the first waveform (S303b, S304b); acquiring a third waveform through the before-and-after difference processing on the second fitting waveform (S305b); acquiring first to third normalized waveforms by normalizing light amount axes and time axes of the first and second fitting waveforms and the third waveform (S306b); extracting a feature quantity from each of the first to third normalized waveforms (S307b); and estimating the cause of extension of the coagulation time of the blood of the specimen to be inspected on the basis of a known feature quantity and the extracted feature quantity.SELECTED DRAWING: Figure 3B

The invention relates to a ginsenoside composition with an effect of regulating blood viscosity as well as a preparation method and application of the ginsenoside composition, and belongs to the technical field of biology. The invention provides a ginsenoside composition. The ginsenoside composition comprises at least two of ginsenoside Rc, ginsenoside Rb2, ginsenoside Rb3, ginsenoside Rd, ginsenoside Rg6, ginsenoside F4, ginsenoside S-Rg3, ginsenoside R-Rg3, ginsenoside PPT, ginsenoside Rk1, ginsenoside Rg5 and ginsenoside Rh2. The ginsenoside composition provided by the invention has the efficacy of improving body weight rise, liver injury, lipid metabolism disorder, insulin level rise and oxidative stress caused by high-fat and high-sugar diet, and has the efficacy of improving blood viscosity rise, blood coagulation time reduction and blood coagulation factor level improvement caused by acute blood stasis; the effects of improving liver injury, blood fat, blood sugar and lipid metabolism disorder, regulating blood viscosity and resisting oxidation can be achieved, and the compound can be expected to be developed into an active raw material to be applied to the fields of biological medicine, cosmetics, food, health care products and the like.

The present inventors produced a variety of bispecific antibodies that specifically bind to both F. IX / F. IXa and F. X, and functionally substitute for F. VIIIa, i.e., have a cofactor function to promote F. X activation via F. IXa. Among these antibodies, the antibody A44 / B26 reduced coagulation time by 50 seconds or more as compared to that observed when the antibody was not added. The present inventors produced a commonly shared L chain antibody from this antibody using L chains of A44, and showed that A44L can be used as commonly shared L chains, although the activity of the resulting antibody is reduced compared to the original antibody (A44HL-B26HL). Further, with appropriate CDR shuffling, the present inventors successfully produced highly active multispecific antibodies that functionally substitute for coagulation factor VIII.

Provided is a coagulation time extension factor estimation method, comprising: 1) obtaining Tm(X) and Tn(X); and 2) estimating a coagulation time extension factor for a test blood sample on the basis of Tm(X), wherein Tm(X) represents a measurement point or a time at which a coagulation reaction curve of sample M reaches X % of coagulation reaction end point Em, Tn(X) represents a measurement point or a time at which a coagulation reaction curve of sample N reaches X % of coagulation reaction end point En, Em is a coagulation reaction end point in the coagulation reaction curve of sample M, En is a coagulation reaction end point in the coagulation reaction curve of sample N, the sample S is a test blood sample having an extended coagulation time, the sample N is a normal blood sample, the sample M is a sample mixture of the sample S and the sample N, and X is larger than 0 and 100 or smaller.

The present inventors produced a variety of bispecific antibodies that specifically bind to both F. IX / F. IXa and F. X, and functionally substitute for F. VIIIa, i.e., have a cofactor function to promote F. X activation via F. IXa. Among these antibodies, the antibody A44 / B26 reduced coagulation time by 50 seconds or more as compared to that observed when the antibody was not added. The present inventors produced a commonly shared L chain antibody from this antibody using L chains of A44, and showed that A44L can be used as commonly shared L chains, although the activity of the resulting antibody is reduced compared to the original antibody (A44HL-B26HL). Further, with appropriate CDR shuffling, the present inventors successfully produced highly active multispecific antibodies that functionally substitute for coagulation factor VIII.